I MAB Stock Quote IMAB - Stock Price, News, Charts, Message Board, Trades

Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

Get Started

Home
Investing
Stocks
USA
NASDAQ
I MAB (IMAB) Quote

I MAB (IMAB)

1.80

-0.01

(-0.55%)

Closed April 28 4:00PM

Delayed by 15 minutes

1.81

0.01

(0.56%)

After Hours: 7:59PM

Delayed by 15 minutes

Unlock more advanced trading tools

Join ADVFN today

Current Price

1.80

Bid

1.79

Ask

1.84

Volume

88,595

1.7999 Day's Range 1.83

0.00 52 Week Range 0.00

Market Cap

Previous Close

1.81

Open

1.81

Last Trade

Last Trade Time

Financial Volume

$ 160,224

VWAP

1.8085

Average Volume (3m)

-

Shares Outstanding

-

Dividend Yield

-

PE Ratio

-

Earnings Per Share (EPS)

-

Revenue

-

Net Profit

-

I-Mab Biopharma is a clinical-stage biotech company in China that listed on Nasdaq in January 2020. Its first commercial drug will be felzartamab for the China market, a CD38 inhibitor for multiple myeloma, which we estimate will be launched in 2022. Core assets include eftansomatropin, a long-actin... I-Mab Biopharma is a clinical-stage biotech company in China that listed on Nasdaq in January 2020. Its first commercial drug will be felzartamab for the China market, a CD38 inhibitor for multiple myeloma, which we estimate will be launched in 2022. Core assets include eftansomatropin, a long-acting recombinant human growth hormone,or rhGH; lemzoparlimab, a potential best-in-class CD47 inhibitor; uliledlimab, a potential best-in-class CD73 inhibitor; and efineptakin alfa, a potential first-in-class long-acting IL-7 drug for tumors and treatment-associated lymphopenia. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.i-mabbiopharma.com

Headquarters

Grand Cayman, Cym

Founded

1970

I MAB is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker IMAB. The last closing price for I MAB was $1.81. Over the last year, I MAB shares have traded in a share price range of $ 0.00 to $ 0.00.

I MAB currently has 0 shares outstanding.

I-Mab to Participate at the 23rd Annual Needham Virtual Healthcare Conference

I-Mab to Participate at the 23rd Annual Needham Virtual Healthcare Conference PR Newswire ROCKVILLE, Md., April 5, 2024 ROCKVILLE, Md., April 5, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB), a...

I-Mab Announces Closing of the Divestiture of Business Operations in China

I-Mab Announces Closing of the Divestiture of Business Operations in China PR Newswire ROCKVILLE, Md., April 2, 2024 ROCKVILLE, Md., April 2, 2024 /PRNewswire/ -- I-Mab (the "Company") (NASDAQ:...

I-Mab Reports Full Year 2023 Financial Results and Business Update

I-Mab Reports Full Year 2023 Financial Results and Business Update PR Newswire ROCKVILLE, Md., March 14, 2024 Recently announced agreement to divest assets and business operations in China marks...

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

Form 144 - Report of proposed sale of securities

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

I-Mab Signs Agreement to Divest its Assets and Business Operations in China

I-Mab Signs Agreement to Divest its Assets and Business Operations in China PR Newswire ROCKVILLE, Md., Feb. 7, 2024 Agreement marks an important milestone to advance the Company's intent to...

Form SCHEDULE 13G - Statement of acquisition of beneficial ownership by individuals

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 144 - Report of proposed sale of securities

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
BDRXBiodexa Pharmaceuticals PLC	$ 1.3254 (82.86%)	70.82M
IBRXImmunityBio Inc	$ 7.35 (43.84%)	40.28M
AGENAgenus Inc	$ 11.685 (40.78%)	3.37M
ULHUniversal Logistics Holdings Inc	$ 45.63 (38.74%)	484.22k
NIVFNewGenIvf Group Ltd	$ 1.77 (36.15%)	57.78M
MFImF International Ltd	$ 2.3153 (-77.82%)	21.23M
NWGLNature Wood Group Ltd	$ 5.05 (-70.03%)	2.48M
ICLKiClick Interactive Asia Group Ltd	$ 1.21 (-52.17%)	719.95k
NUWENewellis Inc	$ 0.1695 (-41.35%)	18.46M
SGBXSafe and Green Holdings Corporation	$ 0.1469 (-32.92%)	8.39M
PEGYPineapple Energy Inc	$ 0.065499 (26.20%)	325.57M
SQQQProShares UltraPro Short QQQ	$ 11.43 (-4.75%)	137.28M
INTCIntel Corporation	$ 31.88 (-9.20%)	119.84M
TSLATesla Inc	$ 168.29 (-1.11%)	109.84M
SOFISoFi Technologies Inc	$ 7.87 (3.69%)	88.63M

Monksdream

Monksdream 4 weeks ago

IMAB 10Q due 4/3

Monksdream

Monksdream 1 month ago

Monksdream

Monksdream 1 month ago

Monksdream

Monksdream 2 months ago

AGORDON

AGORDON 3 months ago

IMAB
This is a long-term deal. The China divestiture had to be done to facilitate the future sale of the company. There would be too many Chinese entities to satisfy and hence introduce uncertainty in a future sale. The loss of the Jumpcan deal is a negative because the numbers were spelled out. I will feel much more comfortable about IMAB after they get a Giva or a Uli licensing deal. Combined, based on prior deals for similar drugs would be worth $1B+. It is likely they will have to pay out $30M to the non participants. The $80M from Hangzhou will take years to collect. But, there is one point that has not been addressed. That is the pricing of drugs in China. The Chinese government is notorious for asking for discounts. The pricing of drugs in the USA is better. IMAB has shifted its focus to drugs in a market where they will get much better pricing. The unknown is will IMAB get a deal for Giva, or Uli ?

AGORDON

AGORDON 4 months ago

2-3 minutes before the close over 500k shares were dumped. Same exercise happened to several Chinese stocks.

AGORDON

AGORDON 4 months ago

Based on the Astra Zeneca agreement with KYM for their Claudin 18.2 drug, and the Antengene agreement with Calithera for their CD73 inhibitor drug, I estimate that IMAB has potential contracts worth $1.25B+.

AGORDON

AGORDON 4 months ago

Why doesn't IMAB license Givasgtomig and Ulilidimab? I estimate that the milestone payments would be at least $500M. The share would be at least $5.

AGORDON

AGORDON 5 months ago

From the 20-F report

On July 16, 2022, I-Mab Hangzhou entered into a definitive financing agreement with a group of domestic investors in China to raise approximately US$46 million (in RMB equivalent). On the same date, we, through our wholly-owned subsidiary, entered into a shareholders agreement with I-Mab Hangzhou and other domestic investors in I-Mab Hangzhou named therein (the “I-Mab Hangzhou Shareholders Agreement”). Upon the occurrence of certain triggering events as specified in the I-Mab Hangzhou Shareholders Agreement, including but not limited to I-Mab Hangzhou’s failure to accomplish certain public offering condition, we may be obligated to repurchase the equity held by other domestic investors in cash or in our stocks in the period beyond 12 months.

AGORDON

AGORDON 5 months ago

In the most recent reporting period, Decheng Capital purchased 4 million shares of IMAB.

AGORDON

AGORDON 5 months ago

The stock has bounced off $1.80 two times within a month.

AGORDON

AGORDON 6 months ago

Not a surprise to see a pull back from the +50% rise last week. A large order came in at the end of yesterday. Nevertheless, it is disappointing to see the slide. It could fall back to $1.28. Mr. Kannan will be at a conference on 11/14. I think the China approvals will send the stock past $3 next year. The company will be sold by the end of 2025.

Mt. Blanc

Mt. Blanc 6 months ago

IMAB climbing the charts tracking the $3s. Check it out soon.

mb

Monksdream

Monksdream 7 months ago

Delayed Upgrade Clock

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions